Ranbaxy Pharmaceuticals Canada Inc. (RPCI), the wholly owned subsidiary of Indian pharma major Ranbaxy Laboratories Limited (RLL).
Ranbaxy Pharmaceuticals Canada Inc. (RPCI), the wholly owned subsidiary of Indian pharma major Ranbaxy Laboratories Limited (RLL), has entered into a tie-up with Janssen-Ortho Inc. (JOI) for marketing of its generic painkiller Fentanyl in Canada.
The second product to be commercialised by RPCI, Fentanyl would be sold under Ranbaxy's label RAN under the licensing and supply agreement with Janssen-Ortho Inc, the company said in a statement Friday."This agreement, which also includes Risperidone, will provide Ranbaxy with an opportunity to commercialise products that continue to have a favourable impact on patient care, as well as on the Canadian healthcare system, and allow Ranbaxy to reinforce its presence in Canada," said Bill Abboud, RPCI president and general manager.
RPCI is the first India-based pharmaceutical company with a generic presence in Canada, the eighth largest pharmaceutical market in the world.
Source-IANS
SRM
